Company news

Aquestive Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

January 12, 2025

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

December 18, 2024

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

December 1, 2024

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

November 11, 2024

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 3, 2024

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American Coll...

October 24, 2024

Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film

October 23, 2024

Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8: 00 a.m. ET

October 20, 2024

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

September 26, 2024

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

September 8, 2024

Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™

August 13, 2024

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 5, 2024

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

July 24, 2024

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8: 00 a.m. ET

July 22, 2024

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

June 26, 2024

Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film

June 24, 2024

Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

June 17, 2024

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

June 2, 2024

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference

May 27, 2024

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

May 8, 2024

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film

April 28, 2024

Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8: 00 a.m. ET

April 24, 2024

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

April 11, 2024

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

March 31, 2024

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

March 24, 2024

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

March 18, 2024

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

March 18, 2024

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

March 13, 2024

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

March 4, 2024

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8: 00 a.m. ET

February 20, 2024

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

February 14, 2024

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

January 29, 2024

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

December 4, 2023

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

November 9, 2023

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 5, 2023

Aquestive Therapeutics Completes $45 Million Debt Refinancing

November 1, 2023

Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8: 00 a.m. ET

October 30, 2023

Aquestive Therapeutics Provides Business Update

October 8, 2023

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

September 19, 2023

Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

September 10, 2023

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 6, 2023

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

August 1, 2023

Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film

July 26, 2023

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8: 00 a.m. ET

July 24, 2023

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference

July 24, 2023

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit

July 5, 2023

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

June 28, 2023

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

May 30, 2023

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 31 calls. Every call is listed under its year.

Decks

The 5 newest of 59 decks. Every deck is listed under its year.